The impact of centralized volume-based procurement policy on the pharmaceutical industry:Review based on the SCP paradigm / 中国卫生政策研究

ABSTRACT

Objective:To systematically review the impact of Chinese centralized volume-based procurement(VBP)policy on the pharmaceutical industry.Methods:Relevant literature published between January 1,2019 and July 31,2023 were retrieved from the database of CNKI,WanFang data,PubMed,and Web of Science.A thematic analysis framework was constructed for data collation and analysis applying the Structure-Conduct-Performance(SCP)paradigm.Results:Forty-one studies were included,with 10(24.4%),24(58.5%),and 23(56.1%)reporting the dimension of structure,conduct,and performance,covering 10 secondary themes.Literature shows that,in terms of market structure,the market share of bid-winning enterprises increased after VBP policy,and the concentration ratio of pharmaceutical industry promoted;as for enterprise conduct,the R&D investment of both bid-winning and bid-non-winning enterprises increased under policy implementation,and the selling expenses on policy-covered products significantly reduced while policy-uncovered products did not;as for industry performance,the impact of VBP policy on operational performance varies among enterprise,and the initially positive effect on promoting innovative output of bid-winning enterprises was observed.Conclusions:The VBP policy has shown positive effects in optimizing market structure,guiding enterprise conduct,and improving industry performance.To consolidate and expand policy effects,it is recommended to further strengthen the comprehensive management of drug prices,expand the boundaries of the VBP market,and strengthen policy monitoring and tracking research.